Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection

Bibliography

• Armstrong GL, Wasley A, Simard EP, The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705-14
   PubMed Web of Science ®Google Scholar
• WHO. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6(1):35-47
   PubMedGoogle Scholar
• Ghany MG, Strader DB, Thomas DL, Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
   PubMed Web of Science ®Google Scholar
• Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008;47(4):1371-83
   PubMed Web of Science ®Google Scholar
• Ferenci P. Treatment of chronic hepatitis C–are interferons really necessary? Liver Int 2012;32 Suppl 1:108-12
   PubMed Web of Science ®Google Scholar
• Ahad MA, Alim MA, Ekram Saifuddin ARM. Interferon to PEG-interferon: a review. J Teach Assoc 2004;17:113-16
   Google Scholar
• Crotty S, Cameron C, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 2002;80(2):86-95
   PubMed Web of Science ®Google Scholar
• Feld JJ, Lutchman GA, Heller T, Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010;139(1):154-62
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364(25):2417-28
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014-24
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207-17
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65
   PubMed Web of Science ®Google Scholar
• Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012;32(Suppl 1):88-102
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL, Evans MJ, von Hahn T, Studying hepatitis C virus: making the best of a bad virus. J Virol 2007;81(17):8853-67
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132(5):1979-98
   PubMed Web of Science ®Google Scholar
• Murakami E, Tolstykh T, Bao H, Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010;285(45):34337-47
   PubMed Web of Science ®Google Scholar
• Sofia MJ, Bao D, Chang W, Discovery of a beta-d-2′-Deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010;53(19):7202-18
   PubMed Web of Science ®Google Scholar
• Murakami E, Niu C, Bao H, The mechanism of action of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008;52(2):458-64
   PubMed Web of Science ®Google Scholar
• Personal Communication with Gilead Sciences
   Google Scholar
• Cornpropst M, Denning J, Clemons D, The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977. EASL 47th Annual Meeting. Barcelona, Spain; 2012
   Google Scholar
• Lawitz E, Rodriguez-Torres M, Cornpropst M, The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected subjects treated for seven days. EASL 47th Annual Meeting. Barcelona, Spain; 2012
   Google Scholar
• Mathias A, Cornpropst M, Clemons D, No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers (abstract 1869). 63rd Meeting of the AASLD. Boston, MA; 2012
   Google Scholar
• Denning J, Cornpropst M, Clemons D, Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone PK and PD. 62th Annual Meeting of the AASLD. San Francisco, CA; 2011
   Google Scholar
• Gane E, Stedman C, Hyland C, Once daily sofosbuvir (GS-7977) regimens in HCV genotype 1-3: the Electron trial. 63rd Annual Meeting of the AASLD. Boston, MA; 2012
   Google Scholar
• Lawitz E, Lalezari J, Hassanein T, PROTON: PSI-7977 & Peg/RBV in Treatment-naïve Patients with HCV GT1: Sustained Virologic Response. 62th Annual Meeting of the AASLD. San Francisco, California; 2011
   Google Scholar
• Lalezari J, Lawitz E, Rodriguez-Torres M, PROTON Study: PSI-7977 QD with PEG/RBV: 12-week Safety, RVR, cEVR, & SVR12 in treatment-naïve patients with HCV GT2 or GT3. EASL 2012. Berlin, Germany; 2011
   Google Scholar
• Gane EJ, Stedman CA, Hyland RH, Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368(1):34-44
   PubMed Web of Science ®Google Scholar
• Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes [Press Release]. 2011. Available from: http://www.prnewswire.com/news-releases/pharmasset-initiates-quantum-a-phase-2b-interferon-free-trial-of-psi-7977-and-psi-938-for-all-hcv-genotypes-129711203.html [Cited 08/01/2012]
   Google Scholar
• Pharmasset Announces Intent to Amend QUANTUM Trial [Press Release]. 2011. Available from: http://www.prnewswire.com/news-releases/pharmasset-announces-intent-to-amend-quantum-trial-135725843.html [Cited 08/01/2012]
   Google Scholar
• Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients. [Press Release]. 2012. Available from: http://www.gilead.com/pr_1684792
   Google Scholar
• Kowdley K, Lawitz E, Crespo I, GS-7977 + PEG/RBV in HCV Genotype 1. The ATOMIC Trial An End To Response-Guided Therapy EASL 47th Annual Meeting. Barcelona, Spain; 2012
   Google Scholar
• Hassanein T, Lawitz E, Crespo I, Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naive patients with HCV genotype 1, 4, and 6 infection in the ATOMIC study [abstract]. 63rd Annual Meeting of the AASLD. Boston, MA; 2012
   Google Scholar
• Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV [Press Release]. 2011. Available from: http://www.prnewswire.com/news-releases/pharmasset-announces-the-initiation-of-an-interferon-free-phase-3-program-with-psi-7977-for-hcv-132983468.html [Cited 08/01/2012]
   Google Scholar
• GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION). 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01604850?term=gs-7977&rank=1 [Cited 7/26/12]
   Google Scholar
• Phase 3 Study of PSI-7977 and Ribavirin (FISSION). 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT01497366 Cited 7/26/12]
   Google Scholar
• GS-7977 + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 HCV Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (POSITRON). 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01542788?term=gs-7977&rank=4 [Cited 7/26/12]
   Google Scholar
• GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection (NEUTRINO). 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01641640?term=gs-7977&rank=3 [Cited 7/26/12]
   Google Scholar
• Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01625338?term=gs-7977&rank=2 [Cited 7/26/12]
   Google Scholar
• Jacobson I, Lawitz E, Lalezari J, GS-7977 400 mg QD safety and tolerability in Over 500 patients treated for at least 12 weeks. 47th Annual Meeting of the EASL. Barcelona, Spain; 2012
   Google Scholar
• Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46(1):78-84
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, High rate of sustained virologic Response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (Nucleotide NS5B inhibitor), with or without ribavirin in treatment-naïve patients chronically infected with HCV GT 1, 2 or 3 (abstract LB-2). 63rd Meeting of the AASLD. Boston, MA; 2012
   Google Scholar
• Gilead Sciences. Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV. 2012. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01701401?term=gs-5885&rank=2 [Last Accessed 12/21/12]
   Google Scholar
• McHutchison JG, Everson GT, Gordon SC, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360(18):1827-38
   PubMed Web of Science ®Google Scholar
• McCown MF, Rajyaguru S, Kular S, GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009;53(5):2129-32
   PubMed Web of Science ®Google Scholar